Qiagen (QGEN) reported $501.87 million in revenue for the quarter ended September 2024, representing a year-over-year increase of 5.5%. EPS of $0.57 for the same period compares to $0.52 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $490.53 million, representing a surprise of +2.31%. The company delivered an EPS surprise of +5.56%, with the consensus EPS estimate being $0.54.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall St ...

Core Viewpoint - Qiagen reported quarterly earnings of $0.57 per share, exceeding the Zacks Consensus Estimate of $0.54 per share, and showing an increase from $0.52 per share a year ago, representing an earnings surprise of 5.56% [1] Financial Performance - The company posted revenues of $501.87 million for the quarter ended September 2024, surpassing the Zacks Consensus Estimate by 2.31%, and up from $475.89 million year-over-year [2] - Over the last four quarters, Qiagen has exceeded consensus EPS estimates three times and topped consensus revenue estimates four times [2] Stock Performance and Outlook - Qiagen shares have declined approximately 1.8% since the beginning of the year, contrasting with the S&P 500's gain of 21.2% [3] - The current consensus EPS estimate for the upcoming quarter is $0.59 on revenues of $522.77 million, and for the current fiscal year, it is $2.15 on revenues of $1.97 billion [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Qiagen belongs, is currently ranked in the top 38% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]

FDA Clearance and Product Innovation - The US FDA has cleared the QIAstat-Dx Meningitis/Encephalitis Panel for clinical use, marking the fourth QIAstat-Dx syndromic test to receive US regulatory clearance in 2024 [1] - The QIAstat-Dx Meningitis/Encephalitis Panel leverages real-time PCR technology to simultaneously analyze multiple genetic targets, providing results in about one hour, compared to traditional methods that require at least 24 hours [2][3] - The QIAstat-Dx system provides cycle threshold (Ct) values and amplification curves, offering additional clinical information not available with traditional end-point PCR or other techniques [4] Market and Industry Context - Bacterial meningitis cases in the US have reached their highest levels since 2014, with case numbers varying by state depending on vaccination rates [2] - Many US healthcare facilities still rely on traditional microbiological testing, which lacks sensitivity and requires longer processing times [2] - The QIAstat-Dx system addresses the need for rapid, evidence-based diagnostics in community-acquired meningitis and encephalitis, which are medical emergencies requiring immediate treatment [3] Product Portfolio and Operational Efficiency - The QIAstat-Dx Meningitis/Encephalitis Panel is the fourth FDA-cleared QIAstat-Dx panel in 2024, following clearances for the Gastrointestinal Panel 2, Respiratory Panel Plus, and Respiratory Panel Mini [4] - All QIAstat-Dx panels are available as cost-efficient, single-use cartridges that simplify test setup, requiring less than a minute and no precision pipetting [4] - The system’s software interprets signals from the reaction and provides positive or negative results for each pathogen, offering one of the simplest workflows for syndromic testing on the market [4] Company Overview - QIAGEN is a Netherlands-based holding company and a leading global provider of Sample to Insight solutions, enabling molecular insights from biological samples [6] - The company serves over 500,000 customers worldwide in Molecular Diagnostics and Life Sciences, with more than 5,900 employees across over 35 locations as of June 30, 2024 [6][7]

Germantown, Maryland, and Venlo, the Netherlands, Oct. 29, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that the U.S. Food and Drug Administration (FDA) has cleared the QIAstat-Dx Respiratory Panel Mini test for clinical use. It is the third test to receive FDA clearance for use with QIAstat-Dx systems in 2024. The QIAstat-Dx Respiratory Panel Mini is designed to support clinical decision making in diagnosing upper respiratory infections in outpatient settings ...

QIAGEN N.V. (QGEN) is well-poised to grow in the coming quarter, driven by its strategic alliances with researchers and pharma companies. The company's expansive next-generation sequencing (NSG) portfolio continues to be bolstered by several innovations. Meanwhile, QIAGEN's operations are vulnerable to currency fluctuations, which can adversely affect its financial results. Competitive disadvantages also add to the worry. In the past year, this Zacks Rank #3 (Hold) stock has risen 6% compared with 4% growth ...

Venlo, the Netherlands, Sept. 26, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that its QIAstat-Dx syndromic testing systems and associated assays have received CE-marking under the European Union's new In-Vitro Diagnostic Medical Devices Regulation (IVDR). This certification includes the widely-used QIAstat-Dx Analyzer, QIAstat-Dx Rise, and panels for detecting gastrointestinal and respiratory illnesses. The achievement underscores QIAGEN's commitment to meeti ...

Core Viewpoint - QIAGEN N.V. and Becton, Dickinson and Company have launched the PAXgene Urine Liquid Biopsy Set, which aims to enhance the analysis of cell-free DNA from urine, addressing a significant market need for reliable urine collection and stabilization solutions [1][7]. Company Developments - The PAXgene Urine Liquid Biopsy Set features a verified, standardized, and complete preanalytical workflow for urine collection, stabilization, and cfDNA isolation, making it compatible with various molecular testing technologies [2][6]. - Following the launch, QIAGEN's shares experienced a decline of 1.7%, closing at $44.11, although the company is expected to benefit from synergies within its Sample Technologies product portfolio [3]. - QIAGEN's market capitalization stands at $10.15 billion, with a recent earnings surprise of 5.77% and a trailing four-quarter average earnings surprise of 2.64% [4]. Product Significance - The PAXgene set is designed to facilitate urine liquid biopsy, which has the potential to aid in detecting minimal residual disease, monitoring treatment responses, and identifying therapeutic targets, thus complementing blood plasma analysis [7]. - This product will complement QIAGEN's existing liquid biopsy solutions, covering a wide range of analytes and molecular detection technologies, thereby enhancing research and clinical applications [8]. Industry Prospects - The global cfDNA testing market was valued at $9.58 billion in 2023 and is projected to grow to $48.03 billion by 2030, with a compound annual growth rate of 25.90%, driven by increasing healthcare expenditure and awareness [10]. - Over the past year, QIAGEN's shares have increased by 8.4%, contrasting with a 0.4% decline in the industry [11].

QIAGEN N.V. (QGEN) recently announced that Bode Technology will be the exclusive global commercial partner for its GEDmatch PRO genealogy database. QIAGEN's subsidiary Verogen inked the deal with Bode. The company has been providing GEDmatch PRO to customers since the acquisition of its subsidiary, Verogen, in early 2023. The latest partnership is aimed at accelerating the use of QIAGEN's next-generation sequencing (NGS) products in human identification (HID) and forensic investigations. QGEN's Likely Stock ...

Venlo, the Netherlands, and Germantown, Maryland, Sept. 23, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that Bode Technology, the largest private U.S. forensics laboratory company with a growing presence in other regions, would become the exclusive global commercial partner for the GEDmatch PRO genealogy database, which is used to assist police and forensic teams with investigative comparisons of genetic data. The multi-year agreement between QIAGEN's sub ...

Core Insights - QIAGEN N.V. has launched 100 new assays for its digital polymerase chain reaction (dPCR) platform, QIAcuity, aimed at studying cancer, genetic disorders, infectious diseases, and environmental monitoring [1][3] - The company has exceeded its 2024 target by launching over 130 new assays year to date, contributing to a total of more than 2,300 validated assays [5] - QIAGEN's market capitalization stands at $10.15 billion, with a recent earnings surprise of 5.77% in the last reported quarter [2] Product Development - The newly launched assays include dPCR LNA Mutation, dPCR CNV Probe Assays, and dPCR Microbial DNA Detection Assays, targeting cancer mutations, copy number variations, and critical pathogens [3][4] - QIAGEN plans to expand its dPCR portfolio into clinical testing with an in-vitro diagnostic version of QIAcuity expected in the second half of 2024 [6] Strategic Collaborations - QIAGEN has entered a collaboration with Eli Lilly to develop a QIAstat-Dx in-vitro diagnostic panel for detecting apolipoprotein E (APOE) genotypes [7] - The company has also expanded its Master Collaboration Agreement with AstraZeneca to develop companion diagnostics for chronic diseases [8] Market Outlook - The global digital PCR market is projected to grow from $7.12 billion in 2024 to $17.33 billion by 2034, with a CAGR of 9.3% [9][10] - Increasing demand for accurate nucleic acid testing in clinical diagnostics and advancements in genomics are key factors driving market growth [10] Financial Performance - QIAGEN's shares have increased by 10.4% over the past year, outperforming the industry growth of 0.3% [11]